ALCESTER, England, September 28, 2017 /PRNewswire/ --
Based on market experience obtained during Quanta's extensive pilot studies, which included over 1000 successful patient treatments at four sites across the UK, the Company has optimised SC+ for commercial launch, anticipated to take place in the second half of 2018. In addition to the small, simple to use and powerful features that set SC+ apart from traditional dialysis machines, state of the art technology upgrades include a new user interface featuring a high resolution and improved touch functionality widescreen and a combined digital health solution.
John E. Milad, Chief Executive Officer of Quanta Dialysis Technologies commented: "We are excited to unveil our new look haemodialysis system today at this important conference for home dialysis. We have listened to the feedback gained from patients, clinicians and nurses during our extensive pilot studies and are pleased to present this new and enhanced version of SC+ to the market which will be the model that we move to commercialisation with in the second half of 2018.
Combined with the advances we have made at the product level, we have also strengthened our team with key additions in engineering and commercial operations that will enable a successful market launch next year. Quanta is now optimally positioned for future commercial success, with a world-leading innovative haemodialysis machine enabling patient led care with better outcomes and an improved quality of life through the continuum of care."
Maddy Warren, Patient Advocate, said: "The number of patients with CKD requiring dialysis is going to increase in the coming years, and we currently have a system where the majority are not offered a real choice or flexibility around how they dialyse, leaving them with very little control over their treatment. Patients very quickly become institutionalised, with most believing they have no other treatment options and resigning themselves to a lack of freedom and normality. The whole concept of dialysis, being totally dependent on a machine to keep you alive, can be daunting and overwhelming; physicians need to help give kidney patients confidence that they can take ownership of their treatment and in doing so can greatly improve their quality of life.
I am extremely passionate about home dialysis and truly believe it is the best form of treatment for many kidney patients, and that is why I'm so excited by the potential of SC+ as it empowers patients with the freedom and flexibility to take back control."
Dr Charlotte Bebb, Consultant Nephrologist at Nottingham University Hospitals NHS Trust and Principal Investigator, said: "The patients who have been treated in Quanta's pilot studies thus far have been extremely positive about their experience with SC+. In order to improve patient outcomes, and experiences, whilst on dialysis I think it is necessary to give patients, and clinicians, greater flexibility and control of their own treatment. I believe this system has the potential to significantly improve the way haemodialysis patients are currently treated."
The UK Annual Dialysis Conference theme for 2017 is 'Dialysis fit for the 21st century', which focuses on the challenges, improvements and outcomes faced by dialysis patients and clinicians in the UK. Patients, clinicians and researchers will explore and discuss topics of clinical interest, including effective integrated home dialysis models, clinical challenges in dialysis practice and quality improvement.
If you would like to arrange a meeting with John E. Milad, Chief Executive Officer, or Peter Hoyer, Chief Commercial Officer, at the conference, please contact [email protected].
SC+ is a unique small, simple and powerful haemodialysis system that supports patients across the continuum of care, from the clinic to the home. SC+ provides clinical efficacy and high flow rates comparable to larger, conventional devices and is compatible with traditional treatment regimens used in-centre. The innovative and patented technology behind SC+ is based on a design breakthrough that allows all dialysate fluid management to be conducted on a small, lightweight, disposable cartridge. This cartridge-based design is intended to reduce downtime, simplify treatment complexity and reduce the risk of contamination.
Quanta aims to improve the lives of dialysis patients by providing advanced haemodialysis solutions for use both in the clinic and the home. Quanta's lead product SC+ is designed to empower dialysis patients by providing them with greater flexibility, convenience and control over the delivery of their life-sustaining renal replacement therapy. Quanta is based in Alcester, UK, and was founded in 2008 as a spin out from IMI plc. The company has attracted funding from a group of leading investors, including: Stage Capital (formerly NBGI Ventures), Wellington Partners, Seroba Life Sciences, b-to-v Partners, ALIAD, Seventure Partners and Kuwait Life Sciences Company, as well as founding partner IMI plc.
For more information, please visit: www.quantadt.com.
For more information about Quanta, please contact: Quanta John E. Milad, Chief Executive Officer T: +44-(0)-1789-400-043 E: [email protected]
Consilium Strategic Communications Amber Fennell / Matthew Neal / Lindsey Neville T: +44-(0)-203-709-5708 E: [email protected]
Subscribe to our Free Newsletters!
Urinary retention is a condition where a person is unable to voluntarily empty the urinary bladder ...
Hashimoto's thyroiditis is an autoimmune disorder of the thyroid causing hypothyroidism. Synthetic ...
Strokes occur when blood flow to an area of the brain is cut off. It is imperitive to detect the ...View All